시장조사 보고서 : 세계의 HER2-음성 유방암 치료 시장예측 2021년-2026년

■ 영문 제목 : Global HER2-negative Breast Cancer Treatment Market Growth (Status and Outlook) 2021-2026
	■ 상품코드 : LPI-2201K00124 ■ 조사/발행회사 : LP Information ■ 발행일 : 2021년 12월 (※2025년 최신판이 있습니다. 문의 주세요.) ■ 페이지수 : 101 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 ■ 조사대상 지역 : 글로벌 ■ 산업 분야 : 의료, 제약

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User (1명 열람용)	USD3,660 ⇒환산￦5,124,000	견적의뢰/주문/질문
Multi User (5명 열람용)	USD5,490 ⇒환산￦7,686,000	견적의뢰/주문/질문
Corporate User (동일기업내 공유가능)	USD7,320 ⇒환산￦10,248,000	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

본 조사보고서는 HER2-음성 유방암 치료의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아, 러시아, 중동/아프리카, 이집트, 남아프리카, 터키, 중동GCC국 등), 시장동향, 판매/유통업자/고객 리스트, 시장예측 (2021년-2026년), 주요 기업동향 (기업정보, 제품, 판매량, 매출, 가격, 매출총이익) 등의 정보를 포함하고 있습니다. 또한, 주요지역의 종류별 시장규모 (화학 요법, 외과, 방사선, 호르몬 요법/내분비 요법)와 용도별 시장규모 (병원, 클리닉) 데이터도 수록되어 있습니다.
- 조사 범위
- 경영자용 요약
- 기업별 HER2-음성 유방암 치료 시장 점유율
- 지역별 HER2-음성 유방암 치료 시장규모
- 주요지역의 종류별 시장규모 (화학 요법, 외과, 방사선, 호르몬 요법/내분비 요법)
- 주요지역의 용도별 시장규모 (병원, 클리닉)
- 미주의 HER2-음성 유방암 치료 시장규모 (미국, 캐나다, 멕시코, 브라질 등)
- 아시아의 HER2-음성 유방암 치료 시장규모 (중국, 일본, 한국, 동남아시아, 인도 등)
- 유럽의 HER2-음성 유방암 치료 시장규모 (독일, 프랑스, 영국, 이탈리아, 러시아 등)
- 중동/아프리카의 HER2-음성 유방암 치료 시장규모 (이집트, 남아프리카, 터키, 중동GCC지역 등)
- 시장의 성장요인, 과제, 동향
- 마케팅, 유통업자, 고객리스트
- 세계의 HER2-음성 유방암 치료 시장예측 (2021년-2026년)
- 주요 기업동향 (기업정보, 제품, 판매량, 매출, 가격, 매출총이익)
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Pfizer, GlaxoSmithKline, Novartis, Merck, Eli Lilly
- 조사의 결과/결론

■ 보고서 개요

According to this latest study, the 2021 growth of HER2-negative Breast Cancer Treatment will have significant change from previous year. By the most conservative estimates of global HER2-negative Breast Cancer Treatment market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the HER2-negative Breast Cancer Treatment market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of HER2-negative Breast Cancer Treatment market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021 in Section 2.3; and forecast to 2026 in section 10.7.
Chemotherapy
Surgery
Radiation
Hormonal therapy/endocrine therapy

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 10.8.
Hosptial
Clinic

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Pfizer
Novartis
Pfizer
GlaxoSmithKline
Novartis
Merck
Eli Lilly

■ 보고서 목차

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global HER2-negative Breast Cancer Treatment Market Size 2016-2026
2.1.2 HER2-negative Breast Cancer Treatment Market Size CAGR by Region 2020 VS 2021 VS 2026
2.2 HER2-negative Breast Cancer Treatment Segment by Type
2.2.1 Chemotherapy
2.2.2 Chemotherapy
2.2.3 Radiation
2.2.4 Hormonal therapy/endocrine therapy
2.3 HER2-negative Breast Cancer Treatment Market Size by Type
2.3.1 Global HER2-negative Breast Cancer Treatment Market Size CAGR by Type
2.3.2 Global HER2-negative Breast Cancer Treatment Market Size Market Share by Type (2016-2021)
2.4 HER2-negative Breast Cancer Treatment Segment by Application
2.4.1 Hosptial
2.4.2 Clinic
2.5 HER2-negative Breast Cancer Treatment Market Size by Application
2.5.1 Global HER2-negative Breast Cancer Treatment Market Size CAGR by Application
2.5.2 Global HER2-negative Breast Cancer Treatment Market Size Market Share by Application (2016-2021)

3 HER2-negative Breast Cancer Treatment Market Size by Players
3.1 HER2-negative Breast Cancer Treatment Market Size Market Share by Players
3.1.1 Global HER2-negative Breast Cancer Treatment Revenue by Players (2019-2021E)
3.1.2 Global HER2-negative Breast Cancer Treatment Revenue Market Share by Players (2019-2021E)
3.2 Global HER2-negative Breast Cancer Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2019-2021E)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 HER2-negative Breast Cancer Treatment by Regions
4.1 HER2-negative Breast Cancer Treatment Market Size by Regions (2016-2021)
4.2 Americas HER2-negative Breast Cancer Treatment Market Size Growth (2016-2021)
4.3 APAC HER2-negative Breast Cancer Treatment Market Size Growth (2016-2021)
4.4 Europe HER2-negative Breast Cancer Treatment Market Size Growth (2016-2021)
4.5 Middle East & Africa HER2-negative Breast Cancer Treatment Market Size Growth (2016-2021)

5 Americas
5.1 Americas HER2-negative Breast Cancer Treatment Market Size by Country (2016-2021)
5.2 Americas HER2-negative Breast Cancer Treatment Market Size by Type (2016-2021)
5.3 Americas HER2-negative Breast Cancer Treatment Market Size by Application (2016-2021)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC HER2-negative Breast Cancer Treatment Market Size by Region (2016-2021)
6.2 APAC HER2-negative Breast Cancer Treatment Market Size by Type (2016-2021)
6.3 APAC HER2-negative Breast Cancer Treatment Market Size by Application (2016-2021)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe HER2-negative Breast Cancer Treatment by Country (2016-2021)
7.2 Europe HER2-negative Breast Cancer Treatment Market Size by Type (2016-2021)
7.3 Europe HER2-negative Breast Cancer Treatment Market Size by Application (2016-2021)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa HER2-negative Breast Cancer Treatment by Region (2016-2021)
8.2 Middle East & Africa HER2-negative Breast Cancer Treatment Market Size by Type (2016-2021)
8.3 Middle East & Africa HER2-negative Breast Cancer Treatment Market Size by Application (2016-2021)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Global HER2-negative Breast Cancer Treatment Market Forecast
10.1 Global HER2-negative Breast Cancer Treatment Forecast by Regions (2021-2026)
10.1.1 Global HER2-negative Breast Cancer Treatment Forecast by Regions (2021-2026)
10.1.2 Americas HER2-negative Breast Cancer Treatment Forecast
10.1.3 APAC HER2-negative Breast Cancer Treatment Forecast
10.1.4 Europe HER2-negative Breast Cancer Treatment Forecast
10.1.5 Middle East & Africa HER2-negative Breast Cancer Treatment Forecast
10.2 Americas HER2-negative Breast Cancer Treatment Forecast by Countries (2021-2026)
10.2.1 United States HER2-negative Breast Cancer Treatment Market Forecast
10.2.2 Canada HER2-negative Breast Cancer Treatment Market Forecast
10.2.3 Mexico HER2-negative Breast Cancer Treatment Market Forecast
10.2.4 Brazil HER2-negative Breast Cancer Treatment Market Forecast
10.3 APAC HER2-negative Breast Cancer Treatment Forecast by Region (2021-2026)
10.3.1 China HER2-negative Breast Cancer Treatment Market Forecast
10.3.2 Japan HER2-negative Breast Cancer Treatment Market Forecast
10.3.3 Korea HER2-negative Breast Cancer Treatment Market Forecast
10.3.4 Southeast Asia HER2-negative Breast Cancer Treatment Market Forecast
10.3.5 India HER2-negative Breast Cancer Treatment Market Forecast
10.3.6 Australia HER2-negative Breast Cancer Treatment Market Forecast
10.4 Europe HER2-negative Breast Cancer Treatment Forecast by Country (2021-2026)
10.4.1 Germany HER2-negative Breast Cancer Treatment Market Forecast
10.4.2 France HER2-negative Breast Cancer Treatment Market Forecast
10.4.3 UK HER2-negative Breast Cancer Treatment Market Forecast
10.4.4 Italy HER2-negative Breast Cancer Treatment Market Forecast
10.4.5 Russia HER2-negative Breast Cancer Treatment Market Forecast
10.5 Middle East & Africa HER2-negative Breast Cancer Treatment Forecast by Region (2021-2026)
10.5.1 Egypt HER2-negative Breast Cancer Treatment Market Forecast
10.5.2 South Africa HER2-negative Breast Cancer Treatment Market Forecast
10.5.3 Israel HER2-negative Breast Cancer Treatment Market Forecast
10.5.4 Turkey HER2-negative Breast Cancer Treatment Market Forecast
10.5.5 GCC Countries HER2-negative Breast Cancer Treatment Market Forecast
10.6 Global HER2-negative Breast Cancer Treatment Forecast by Type (2021-2026)
10.7 Global HER2-negative Breast Cancer Treatment Forecast by Application (2021-2026)

11 Key Players Analysis
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca HER2-negative Breast Cancer Treatment Product Offered
11.1.3 AstraZeneca HER2-negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
11.1.4 AstraZeneca Main Business Overview
11.1.5 AstraZeneca Latest Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Information
11.2.2 Bristol-Myers Squibb HER2-negative Breast Cancer Treatment Product Offered
11.2.3 Bristol-Myers Squibb HER2-negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
11.2.4 Bristol-Myers Squibb Main Business Overview
11.2.5 Bristol-Myers Squibb Latest Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Company Information
11.3.2 Eli Lilly HER2-negative Breast Cancer Treatment Product Offered
11.3.3 Eli Lilly HER2-negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
11.3.4 Eli Lilly Main Business Overview
11.3.5 Eli Lilly Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer HER2-negative Breast Cancer Treatment Product Offered
11.4.3 Pfizer HER2-negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 Novartis
11.5.1 Novartis Company Information
11.5.2 Novartis HER2-negative Breast Cancer Treatment Product Offered
11.5.3 Novartis HER2-negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
11.5.4 Novartis Main Business Overview
11.5.5 Novartis Latest Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer HER2-negative Breast Cancer Treatment Product Offered
11.6.3 Pfizer HER2-negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
11.6.4 Pfizer Main Business Overview
11.6.5 Pfizer Latest Developments
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Information
11.7.2 GlaxoSmithKline HER2-negative Breast Cancer Treatment Product Offered
11.7.3 GlaxoSmithKline HER2-negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
11.7.4 GlaxoSmithKline Main Business Overview
11.7.5 GlaxoSmithKline Latest Developments
11.8 Novartis
11.8.1 Novartis Company Information
11.8.2 Novartis HER2-negative Breast Cancer Treatment Product Offered
11.8.3 Novartis HER2-negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
11.8.4 Novartis Main Business Overview
11.8.5 Novartis Latest Developments
11.9 Merck
11.9.1 Merck Company Information
11.9.2 Merck HER2-negative Breast Cancer Treatment Product Offered
11.9.3 Merck HER2-negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
11.9.4 Merck Main Business Overview
11.9.5 Merck Latest Developments
11.10 Eli Lilly
11.10.1 Eli Lilly Company Information
11.10.2 Eli Lilly HER2-negative Breast Cancer Treatment Product Offered
11.10.3 Eli Lilly HER2-negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
11.10.4 Eli Lilly Main Business Overview
11.10.5 Eli Lilly Latest Developments

12 Research Findings and Conclusion

List of Tables
Table 1. HER2-negative Breast Cancer Treatment Market Size CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Chemotherapy
Table 3. Major Players of Surgery
Table 4. Major Players of Radiation
Table 5. Major Players of Hormonal therapy/endocrine therapy
Table 6. HER2-negative Breast Cancer Treatment Market Size CAGR by Type (2020-2026) & ($ Millions)
Table 7. Global HER2-negative Breast Cancer Treatment Market Size by Type (2016-2021) & ($ Millions)
Table 8. Global HER2-negative Breast Cancer Treatment Market Size Market Share by Type (2016-2021)
Table 9. HER2-negative Breast Cancer Treatment Market Size CAGR by Application (2016-2021) & ($ Millions)
Table 10. Global HER2-negative Breast Cancer Treatment Market Size by Application (2016-2021) & ($ Millions)
Table 11. Global HER2-negative Breast Cancer Treatment Market Size Market Share by Application (2016-2021)
Table 12. Global HER2-negative Breast Cancer Treatment Revenue by Players (2019-2021E) & ($ Millions)
Table 13. Global HER2-negative Breast Cancer Treatment Revenue Market Share by Players (2019-2021E)
Table 14. HER2-negative Breast Cancer Treatment Key Players Head office and Products Offered
Table 15. HER2-negative Breast Cancer Treatment Concentration Ratio (CR3, CR5 and CR10) & (2019-2021E)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global HER2-negative Breast Cancer Treatment Market Size by Regions 2016-2021 & ($ Millions)
Table 19. Global HER2-negative Breast Cancer Treatment Market Size Market Share by Regions 2016-2021
Table 20. Americas HER2-negative Breast Cancer Treatment Market Size by Country (2016-2021) & ($ Millions)
Table 21. Americas HER2-negative Breast Cancer Treatment Market Size Market Share by Country (2016-2021)
Table 22. Americas HER2-negative Breast Cancer Treatment Market Size by Type (2016-2021) & ($ Millions)
Table 23. Americas HER2-negative Breast Cancer Treatment Market Size Market Share by Type (2016-2021)
Table 24. Americas HER2-negative Breast Cancer Treatment Market Size by Application (2016-2021) & ($ Millions)
Table 25. Americas HER2-negative Breast Cancer Treatment Market Size Market Share by Application (2016-2021)
Table 26. APAC HER2-negative Breast Cancer Treatment Market Size by Region (2016-2021) & ($ Millions)
Table 27. APAC HER2-negative Breast Cancer Treatment Market Size Market Share by Region (2016-2021)
Table 28. APAC HER2-negative Breast Cancer Treatment Market Size by Type (2016-2021) & ($ Millions)
Table 29. APAC HER2-negative Breast Cancer Treatment Market Size Market Share by Type (2016-2021)
Table 30. APAC HER2-negative Breast Cancer Treatment Market Size by Application (2016-2021) & ($ Millions)
Table 31. APAC HER2-negative Breast Cancer Treatment Market Size Market Share by Application (2016-2021)
Table 32. Europe HER2-negative Breast Cancer Treatment Market Size by Country (2016-2021) & ($ Millions)
Table 33. Europe HER2-negative Breast Cancer Treatment Market Size Market Share by Country (2016-2021)
Table 34. Europe HER2-negative Breast Cancer Treatment Market Size by Type (2016-2021) & ($ Millions)
Table 35. Europe HER2-negative Breast Cancer Treatment Market Size Market Share by Type (2016-2021)
Table 36. Europe HER2-negative Breast Cancer Treatment Market Size by Application (2016-2021) & ($ Millions)
Table 37. Europe HER2-negative Breast Cancer Treatment Market Size Market Share by Application (2016-2021)
Table 38. Middle East & Africa HER2-negative Breast Cancer Treatment Market Size by Region (2016-2021) & ($ Millions)
Table 39. Middle East & Africa HER2-negative Breast Cancer Treatment Market Size Market Share by Region (2016-2021)
Table 40. Middle East & Africa HER2-negative Breast Cancer Treatment Market Size by Type (2016-2021) & ($ Millions)
Table 41. Middle East & Africa HER2-negative Breast Cancer Treatment Market Size Market Share by Type (2016-2021)
Table 42. Middle East & Africa HER2-negative Breast Cancer Treatment Market Size by Application (2016-2021) & ($ Millions)
Table 43. Middle East & Africa HER2-negative Breast Cancer Treatment Market Size Market Share by Application (2016-2021)
Table 44. Key and Potential Regions of HER2-negative Breast Cancer Treatment
Table 45. Key Application and Potential Industries of HER2-negative Breast Cancer Treatment
Table 46. Key Challenges of HER2-negative Breast Cancer Treatment
Table 47. Key Trends of HER2-negative Breast Cancer Treatment
Table 48. Global HER2-negative Breast Cancer Treatment Market Size Forecast by Regions (2021-2026) & ($ Millions)
Table 49. Global HER2-negative Breast Cancer Treatment Market Size Market Share Forecast by Regions (2021-2026)
Table 50. Global HER2-negative Breast Cancer Treatment Market Size Forecast by Type (2021-2026) & ($ Millions)
Table 51. Global HER2-negative Breast Cancer Treatment Market Size Market Share Forecast by Type (2021-2026)
Table 52. Global HER2-negative Breast Cancer Treatment Market Size Forecast by Application (2021-2026) & ($ Millions)
Table 53. Global HER2-negative Breast Cancer Treatment Market Size Market Share Forecast by Application (2021-2026)
Table 54. AstraZeneca Details, Company Type, HER2-negative Breast Cancer Treatment Area Served and Its Competitors
Table 55. AstraZeneca HER2-negative Breast Cancer Treatment Product Offered
Table 56. AstraZeneca HER2-negative Breast Cancer Treatment Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 57. AstraZeneca Main Business
Table 58. AstraZeneca Latest Developments
Table 59. Bristol-Myers Squibb Details, Company Type, HER2-negative Breast Cancer Treatment Area Served and Its Competitors
Table 60. Bristol-Myers Squibb HER2-negative Breast Cancer Treatment Product Offered
Table 61. Bristol-Myers Squibb Main Business
Table 62. Bristol-Myers Squibb HER2-negative Breast Cancer Treatment Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 63. Bristol-Myers Squibb Latest Developments
Table 64. Eli Lilly Details, Company Type, HER2-negative Breast Cancer Treatment Area Served and Its Competitors
Table 65. Eli Lilly HER2-negative Breast Cancer Treatment Product Offered
Table 66. Eli Lilly Main Business
Table 67. Eli Lilly HER2-negative Breast Cancer Treatment Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 68. Eli Lilly Latest Developments
Table 69. Pfizer Details, Company Type, HER2-negative Breast Cancer Treatment Area Served and Its Competitors
Table 70. Pfizer HER2-negative Breast Cancer Treatment Product Offered
Table 71. Pfizer Main Business
Table 72. Pfizer HER2-negative Breast Cancer Treatment Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 73. Pfizer Latest Developments
Table 74. Novartis Details, Company Type, HER2-negative Breast Cancer Treatment Area Served and Its Competitors
Table 75. Novartis HER2-negative Breast Cancer Treatment Product Offered
Table 76. Novartis Main Business
Table 77. Novartis HER2-negative Breast Cancer Treatment Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 78. Novartis Latest Developments
Table 79. Pfizer Details, Company Type, HER2-negative Breast Cancer Treatment Area Served and Its Competitors
Table 80. Pfizer HER2-negative Breast Cancer Treatment Product Offered
Table 81. Pfizer Main Business
Table 82. Pfizer HER2-negative Breast Cancer Treatment Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 83. Pfizer Latest Developments
Table 84. GlaxoSmithKline Details, Company Type, HER2-negative Breast Cancer Treatment Area Served and Its Competitors
Table 85. GlaxoSmithKline HER2-negative Breast Cancer Treatment Product Offered
Table 86. GlaxoSmithKline Main Business
Table 87. GlaxoSmithKline HER2-negative Breast Cancer Treatment Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 88. GlaxoSmithKline Latest Developments
Table 89. Novartis Details, Company Type, HER2-negative Breast Cancer Treatment Area Served and Its Competitors
Table 90. Novartis HER2-negative Breast Cancer Treatment Product Offered
Table 91. Novartis Main Business
Table 92. Novartis HER2-negative Breast Cancer Treatment Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 93. Novartis Latest Developments
Table 94. Merck Details, Company Type, HER2-negative Breast Cancer Treatment Area Served and Its Competitors
Table 95. Merck HER2-negative Breast Cancer Treatment Product Offered
Table 96. Merck Main Business
Table 97. Merck HER2-negative Breast Cancer Treatment Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 98. Merck Latest Developments
Table 99. Eli Lilly Details, Company Type, HER2-negative Breast Cancer Treatment Area Served and Its Competitors
Table 100. Eli Lilly HER2-negative Breast Cancer Treatment Product Offered
Table 101. Eli Lilly Main Business
Table 102. Eli Lilly HER2-negative Breast Cancer Treatment Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 103. Eli Lilly Latest Developments
List of Figures
Figure 1. HER2-negative Breast Cancer Treatment Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global HER2-negative Breast Cancer Treatment Market Size Growth Rate 2016-2026 ($ Millions)
Figure 6. Global HER2-negative Breast Cancer Treatment Market Size Market Share by Type in 2020
Figure 7. HER2-negative Breast Cancer Treatment in Hosptial
Figure 8. Global HER2-negative Breast Cancer Treatment Market: Hosptial (2016-2021) & ($ Millions)
Figure 9. HER2-negative Breast Cancer Treatment in Clinic
Figure 10. Global HER2-negative Breast Cancer Treatment Market: Clinic (2016-2021) & ($ Millions)
Figure 11. Global HER2-negative Breast Cancer Treatment Market Size Market Share by Application in 2020
Figure 12. Global HER2-negative Breast Cancer Treatment Revenue Market Share by Player in 2020
Figure 13. Global HER2-negative Breast Cancer Treatment Market Size Market Share by Regions (2016-2021)
Figure 14. Americas HER2-negative Breast Cancer Treatment Market Size 2016-2021 ($ Millions)
Figure 15. APAC HER2-negative Breast Cancer Treatment Market Size 2016-2021 ($ Millions)
Figure 16. Europe HER2-negative Breast Cancer Treatment Market Size 2016-2021 ($ Millions)
Figure 17. Middle East & Africa HER2-negative Breast Cancer Treatment Market Size 2016-2021 ($ Millions)
Figure 18. Americas HER2-negative Breast Cancer Treatment Market Size Market Share by Country in 2020
Figure 19. Americas HER2-negative Breast Cancer Treatment Market Size Market Share by Type in 2020
Figure 20. Americas HER2-negative Breast Cancer Treatment Market Size Market Share by Application in 2020
Figure 21. United States HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 22. Canada HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 23. Mexico HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 24. APAC HER2-negative Breast Cancer Treatment Market Size Market Share by Regions in 2020
Figure 25. APAC HER2-negative Breast Cancer Treatment Market Size Market Share by Type in 2020
Figure 26. APAC HER2-negative Breast Cancer Treatment Market Size Market Share by Application in 2020
Figure 27. China HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 28. Japan HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 29. Korea HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 30. Southeast Asia HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 31. India HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 32. Australia HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 33. Europe HER2-negative Breast Cancer Treatment Market Size Market Share by Country in 2020
Figure 34. Europe HER2-negative Breast Cancer Treatment Market Size Market Share by Type in 2020
Figure 35. Europe HER2-negative Breast Cancer Treatment Market Size Market Share by Application in 2020
Figure 36. Germany HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 37. France HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 38. UK HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 39. Italy HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 40. Russia HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 41. Middle East & Africa HER2-negative Breast Cancer Treatment Market Size Market Share by Region in 2020
Figure 42. Middle East & Africa HER2-negative Breast Cancer Treatment Market Size Market Share by Type in 2020
Figure 43. Middle East & Africa HER2-negative Breast Cancer Treatment Market Size Market Share by Application in 2020
Figure 44. Egypt HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 45. South Africa HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 46. Israel HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 47. Turkey HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 48. GCC Country HER2-negative Breast Cancer Treatment Market Size Growth 2016-2021 ($ Millions)
Figure 49. Americas HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 50. APAC HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 51. Europe HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 52. Middle East & Africa HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 53. United States HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 54. Canada HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 55. Mexico HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 56. Brazil HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 57. China HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 58. Japan HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 59. Korea HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 60. Southeast Asia HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 61. India HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 62. Australia HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 63. Germany HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 64. France HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 65. UK HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 66. Italy HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 67. Russia HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 68. Spain HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 69. Egypt HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 70. South Africa HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 71. Israel HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 72. Turkey HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)
Figure 73. GCC Country HER2-negative Breast Cancer Treatment Market Size 2021-2026 ($ Millions)

※본 조사보고서 [세계의 HER2-음성 유방암 치료 시장예측 2021년-2026년] (코드 : LPI-2201K00124) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [세계의 HER2-음성 유방암 치료 시장예측 2021년-2026년] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 조사자료도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

세계의 구강암 치료 시장예측 2021년-2026년
LPI-2201K02096 / LP Information / 2021년 12월 / 본 조사보고서는 구강암 치료의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아,...According to this latest study, the 2021 growth of Mouth Cancer Treatment will have significant change from previous year. By the most conservative estimates of global Mouth Cancer Treatment market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in...

세계의 전이성 암 치료 시장예측 2021년-2026년
LPI-2201K02228 / LP Information / 2021년 12월 / 본 조사보고서는 전이성 암 치료의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국,...According to this latest study, the 2021 growth of Metastatic Cancer Treatment will have significant change from previous year. By the most conservative estimates of global Metastatic Cancer Treatment market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 49140 million in...

세계의 JAK 억제제 베이스 항암제 시장예측 2021년-2026년
LPI-2201K00078 / LP Information / 2021년 12월 / 본 조사보고서는 JAK 억제제 베이스 항암제의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스,...According to this latest study, the 2021 growth of JAK Inhibitor Based Cancer Drug will have significant change from previous year. By the most conservative estimates of global JAK Inhibitor Based Cancer Drug market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from...

세계의 췌장암 치료제 시장예측 2021년-2026년
LPI-2201K02132 / LP Information / 2021년 12월 / 본 조사보고서는 췌장암 치료제의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아,...According to this latest study, the 2021 growth of Pancreatic Cancer Drugs will have significant change from previous year. By the most conservative estimates of global Pancreatic Cancer Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in...

세계의 볼프람 증후군 치료 시장예측 2021년-2026년
LPI-2201K02333 / LP Information / 2021년 12월 / 본 조사보고서는 볼프람 증후군 치료의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국,...According to this latest study, the 2021 growth of Wolfram Syndrome Treatment will have significant change from previous year. By the most conservative estimates of global Wolfram Syndrome Treatment market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in...

세계의 두경부암 치료제 시장예측 2021년-2026년
LPI-2201K00107 / LP Information / 2021년 12월 / 본 조사보고서는 두경부암 치료제의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아,...According to this latest study, the 2021 growth of Head and Neck Cancer Therapeutics will have significant change from previous year. By the most conservative estimates of global Head and Neck Cancer Therapeutics market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from...

세계의 난소암 치료제 시장예측 2021년-2026년
LPI-2201K02256 / LP Information / 2021년 12월 / 본 조사보고서는 난소암 치료제의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아,...According to this latest study, the 2021 growth of Ovarian Cancer Therapeutics will have significant change from previous year. By the most conservative estimates of global Ovarian Cancer Therapeutics market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 1725.9 million in...